Chile: New Laws and Regulations Controlling Pharmaceutical Drug Prices

Published on January 19, 2023

The CENABAST law and the “Drugs 2” bill will have a serious effect on the Chilean pharmaceutical industry. Experts Beatriz Beamonte, Pedro Santana, and Vicente Lumbreras reveal what the changes are and advise manufacturers on how to adapt their strategies accordingly.

The Chilean government is introducing two new laws that aim to control and reduce pharmaceutical drug prices:

  • The CENABAST law (law 21.198), which was passed last year
  • The “Drugs 2” bill (“Fármacos 2” in Spanish)

These changes were motivated by the significant out-of-pocket burden for patients caused by the high drug prices and retail pharmacy margins. In this article we provide an overview of the changes proposed by the government, and the respective commercial implications for pharmaceutical manufacturers.

CENABAST LAW

CENABAST (National Center for Supply) has traditionally been…

Continue reading on website
Other news

What Physics Teaches Us About Provider Based Contracting for Pharmaceuticals

January 19, 2023
The introduction of average sales price based reimbursement (ASP) in 2003, has brought about a challenging landscape for manufacturers of physician-administered medications. However, three lessons from high school physics can help manufacturers better understand provider contracting and manage long-term ASP.One of the peculiarities of the US healthcare system is the handling of physician-administe

Introduction to B2B Dynamic Pricing

January 19, 2023
*//*-->*//*-->*//*-->*//*-->*//*-->*/Having helped multiple B2B clients implement dynamic and digital pricing to achieve 4-6 percent margin improvement, we have launched a new series discussing the growth potential, challenges, and pitfalls of B2B dynamic pricing. In our first article, expert Kiran Pudi outlines why, how, and when B2B dynamic pricing should be developed and employed for commercial